Menu
Hyamedix Innovation Safety Efficacy
Next generation drug products utilizing patented hydrogel technology to improve the delivery, safety and efficacy of APIs
About us
Hyamedix specializes in improving drug delivery and drug release profiles in order to improve their safety and efficacy with the use of a naturally occurring molecule of the human body, Hyaluronan (HA), a well-known, safe, biodegradable and biocompatible molecule. Based on this we develop bespoke drug products combining customized hydrogel formulations with selected APIs for novel/unmet clinical needs.
Our hydrogel technology enables us to package and formulate existing or new APIs in ways that allow for more optimal release and delivery for better safety, efficacy and patient compliance. By optimizing/repurposing these APIs we are also able to target new and novel therapeutic spaces as well as utilizing an accelerated and cost-effective clinical pathway.
With its advanced patented HA modification technology, HyalinkTM X Hyamedix is able to:
Extend
Extend the commercial lifetime of drugs
Improve
Improve patient compliance
Open
Open new market opportunities for existing as well as new drugs (including shelved drugs)
Our Pipeline
Hyamedix is part of a range of active projects at various levels of development. For any information about these projects or to keep up to date with their development please don’t hesitate to contact us.
STAGES OF DEVELOPMENT
Pre-Clinical
Phase 1
Phase 2
Phase 3
Submitted
Approval
Project DX1
Project Gelferon
Project Senso
Elevate Osteo Pty Ltd
Orthapedics Treatment
A patented osteoarthritis product based on extended release of a drug that will be injected intra-articularly to reduce pain and inflammation of arthritic joints to improve quality of life and delay (or avoid) the need for joint replacement.
- Pre Clinical
- Phase 1
- Phase 2
- Phase 3
- Submitted
- Approval
Naris Therapeutics Pty Ltd
COVID Therapeutics
A novel patent pending SARS-CoV2 prophylactic designed to treat viral infections by inducing rapid viral clearance.
- Pre Clinical
- Phase 1
- Phase 2
- Phase 3
- Submitted
- Approval
Nerve Protection Pty Ltd
Nerve Protection
A patented biosurgical product based on slow release of a drug that will be topically applied to an exposed nerve during surgery to reduce intra-axonol cell death or inflammatory pathways.
- Pre Clinical
- Phase 1
- Phase 2
- Phase 3
- Submitted
- Approval
Therapeutic Spaces
Hyamedix is currently present and active in three different therapeutic spaces via separate joint ventures which we own and operate in collaboration with our partner, Intravital Pty Ltd, in Australia.
Naris Therapeutics Pty Ltd
Most nasal sprays are cleared from the nasal cavity and ingested within 15-20 minutes. This barrier limits the feasibility of nasal sprays to select therapies. Based on a new platform technology of sprayable hydrogels, Naris Therapeutics is able to deliver therapies that stay localised to the nasal cavity where they can be slowly released for optimal therapeutic effect. The spray is undetectable following use, with no leakage, sensation or ingestion.
Nerve Protection Pty Ltd
Surgical nerve injury is common, debilitating and largely preventable. All surgery creates trauma which drives an inflammatory and cell death process in exposed nerves. This directly causes impaired function, pain and misery. Nerve Protection Pty Ltd’s novel gel and first-in-class therapy treats nerves at the time of surgery, preventing the fallout and improving surgical outcomes.
Elevate Osteo Pty Ltd
Elevate Osteo is developing a next generation treatment which immediately improves symptoms of arthritis while protecting cartilage and accelerating healing in damaged joints.
Executive Management
TODD KENWORTH
Founder, CEO and Chairman of the Board of Directors
Mr. Kenworth is a co-founder of Hyamedix, ApS and has served as our Chief Executive Officer since our inception in 2017. He also serves as the Chairman of the board of directors. He has over 20 years’ experience in the biotechnology sector and specifically within Hyaluronic Acid production, modification and product development.
Michael Foldager
Founder, COO and Member of the Board of Directors
Mr. Foldager is a co-founder of Hyamedix, ApS and has served as our Chief Operations Officer since our inception in 2017. He also serves on the Board of Directors. He has over 10 years’ experience in the biotechnology sector and specifically within Hyaluronic Acid production, modification and product development.
BIRGIT FUHLENDORFF
Head of Formulation Development
Ms. Fuhlendorff has served as Head of Formulation Development and Head of Hyamedix Labs since 2018. She has over 20 years’ experience in the biotechnology sector and specifically within Hyaluronic Acid production, modification and product development.
Our Technology
Hyalink™ X
Hyalink™ X is our patented Hyaluronan (HA) cross linking technology (Hydrogels & Dry matrices) that is a versatile and proven technology with customized properties that are well tolerated, safe and biocompatible – 2 decades of use with millions of patient injections. It has many desirable properties for advanced medical applications.
Partnership Opportunities
Strategy
Hyamedix is building an innovative portfolio of first-in-class drug products that improve and broaden the use of existing APIs as well as pave the way for new and innovative combination therapies.
What we are seeking
We are actively seeking new partners with compounds that are in need of delivery platforms that improve the delivery, efficacy and safety of the drugs in question, so if you would like to explore partnering opportunities with us and understand how our team of leading experts could help advance your asset, please contact info@hyamedix.com.
News
Press Release
1st April 2021
Hyamedix ApS Receives Funding to Accelerate Growth of Key Pipeline Projects.
Hyaluronan Conference 2021
14th - 15th of June, 2021
Virtual
Hyamedix will be attending virtually the Hyaluronan Conference 2021.
7th International Polysaccharide Conference
11th - 15th of October, 2021
Nantes, France
Hyamedix will be attending the 7th International Polysaccharide Conference.
Media & Publications
BY JEFFREY KROIN ET AL Published 24.06.16
Intraarticular steroid injection has been the mainstay of short-term treatment of knee osteoarthritis (OA) pain. However, the duration of therapeutic effect from a single injection is not as long as desired. In this study we use a viscous formulation of triamcinolone acetate (TCA) in hyaluronic acid to prolong the anti-allodynia effect of that steroid.
BY KEVIN GRØNNEMANN Published 06.08.19 at 07:37
A group of former Novozymes employees have founded their own biotech company, Hyamedix, to continue development of a medical technology based on hyaluronic acid. Novozymes scrapped the technology in 2015 but the new company has high aspirations.
BY METTE LOUISE OHANA 2019.08.08
A technique for printing soft parts using a 3D printer which can, among other things, replace transplanted tissue, has just been outsourced to the company Hyamedix. Assistant Professor Dang Quang Svend Le from Aarhus University and Aarhus University Hospital is the man behind the invention.
Address List
- Copenhagen Bio Science Park, Ole Maaløes Vej 3, 2200 Copenhagen, Denmark
- +45 53 52 00 44
- info@hyamedix.com
